Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | CFTR | P13569 | 7/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.51 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11550177 | 0.94 | L3MBTL1 (0.52) | L3MBTL1CFTROPRK1KMT2AALOX5 | |
| SCHEMBL11544946 | 0.91 | L3MBTL1 (0.48) | L3MBTL1CFTROPRK1KMT2AALOX5 | |
| SCHEMBL11160397 | 0.87 | L3MBTL1 (0.57) | L3MBTL1CFTROPRK1KMT2AALOX5 | |
| SCHEMBL11604828 | 0.87 | KMT2A (0.60) | L3MBTL1CFTROPRK1KMT2A | |
| SCHEMBL11159597 | 0.86 | L3MBTL1 (0.53) | L3MBTL1CFTROPRK1KMT2APLA2G2A | |
| SCHEMBL11540068 | 0.86 | L3MBTL1 (0.50) | L3MBTL1CFTROPRK1KMT2AALOX5 | |
| SCHEMBL3472479 | 0.86 | CFTR (0.56) | L3MBTL1CFTROPRK1KMT2AALOX5 | |
| SCHEMBL11167732 | 0.85 | MAPT (0.61) | L3MBTL1OPRK1KMT2A | |
| SCHEMBL3469784 | 0.85 | CFTR (0.57) | L3MBTL1CFTROPRK1KMT2AALOX5 | |
| SCHEMBL3470351 | 0.85 | CFTR (0.57) | L3MBTL1CFTROPRK1KMT2AALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2191832-A1 | QUINAZOLINE DERIVATIVES WHICH PROMOTE THE RELEASE OF PARATHYROID HORMONE | Novartis AG (CH) | 2010-06-02 | — | — | EP | claimed |
| US-20040180912-A1 | Quinazoline derivatives | NOVARTIS AG (CH) | 2004-09-16 | — | — | US | claimed |
| EP-1401451-A2 | QUINAZOLINE DERIVATIVES WHICH PROMOTE THE RELEASE OF PARATHYROID HORMONE | Novartis AG (CH) | 2004-03-31 | — | — | EP | claimed |
| WO-2002102782-A2 | QUINAZOLINE DERIVATIVES which PROMOTE THE RELEASE OF PARATHYROID_HORMONE | NOVARTIS AG (CH) | 2002-12-27 | — | — | WO | claimed |
| US-8476286-B2 | for promoting the release of parathyroid hormone, e.g. for preventing or treating bone conditions which are associated with increased calcium depletion or resorption or in which stimulation of bone formation and calcium fixation in the bone is desirable | NOVARTIS AG (CH) | 2013-07-02 | — | — | US | disclosed |
| EP-2191832-A1 | QUINAZOLINE DERIVATIVES WHICH PROMOTE THE RELEASE OF PARATHYROID HORMONE | Novartis AG (CH) | 2010-06-02 | — | — | EP | disclosed |
| US-20040180912-A1 | Quinazoline derivatives | NOVARTIS AG (CH) | 2004-09-16 | — | — | US | disclosed |
| EP-1401451-A2 | QUINAZOLINE DERIVATIVES WHICH PROMOTE THE RELEASE OF PARATHYROID HORMONE | Novartis AG (CH) | 2004-03-31 | — | — | EP | disclosed |
| WO-2002102782-A2 | QUINAZOLINE DERIVATIVES which PROMOTE THE RELEASE OF PARATHYROID_HORMONE | NOVARTIS AG (CH) | 2002-12-27 | — | — | WO | disclosed |
| US-4387223-A | Process for preparing 2(1H)-quinazolinone derivatives | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1983-06-07 | — | — | US | disclosed |
| US-4096144-A | Process for preparing quinazolinone derivatives and their 2-(N-mono-substituted amino)-phenyl ketone intermediate derivatives | SUMITOMO CHEMICAL COMPANY, LIMITED (JA) | 1978-06-20 | — | — | US | disclosed |
| US-3953446-A | Process for preparing quinazolines | SUMITOMO CHEMICAL COMPANY, LIMITED (JA) | 1976-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180912-A1 | Quinazoline derivatives | PTH1R, PTMS, CALCA | L3MBTL1 4552/4885CFTR 2853/4885OPRK1 2236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.